FDA extends deadline to decide on Gamida Cell's stem cell transplant therapy by three...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 22, 2022 at 04:32: PM
via With commercial preparations already underway, Gamida Cell was keenly eyeing the late January deadline for U.S. regulators to decide on the approval application of its stem cell transplant therapy.

article source
 

<



Similar threads

cafead
FDA extends Class I UDI submission deadline, exempts consumer health devices from requirements
Replies
0
Views
103
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO: AstraZeneca&#039;s Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?
Replies
0
Views
23
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Another delay for Ascendis&#039; hormone therapy as FDA extends review by 3 months
Replies
1
Views
208
Pharma/Biotech Companies - In the News
anonymous
cafead
CEL-SCI&#039;s multi-decade Multikine journey extends with FDA request for new trial
Replies
0
Views
112
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Regeneron&#039;s bid for COVID-19 drug&#039;s full approval hits snag as FDA extends review
Replies
0
Views
338
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote